Whole genome sequencing and whole exome sequencing are ways to examine large amounts of DNA. Their names describe the breadth of the sequencing approach. They do not promise an explanation for every symptom, a forecast of every future illness, or a report on every genetic difference that is detected.
The central comparison is straightforward: exome sequencing focuses on protein-coding regions, while genome sequencing extends across coding and noncoding DNA. The harder questions concern what a particular laboratory can detect reliably, what it will analyze, and how the findings relate to the reason for testing. Our introduction to human genome testing places both methods within the wider testing landscape.
What does each approach examine?
The exome is the collection of exons, including the regions that provide instructions for making proteins. These represent only a small proportion of the genome. Many established disease-associated variants affect protein-coding regions, which makes exome sequencing a useful way to investigate a broad set of genes without sequencing the entire genome.
Whole genome sequencing aims to examine DNA across the genome, including regions outside protein-coding genes. Some noncoding regions help regulate gene activity, and changes in them can be relevant to genetic conditions. The MedlinePlus explanation of exome and genome sequencing describes this difference in scope and emphasizes that the significance of many detected changes remains unknown.
For background on what the genome contains, read our guide to genomic DNA. The distinction between coding and noncoding DNA is about biological function and test design; it is not a division between useful DNA and dispensable DNA.
Keep three layers of scope separate
A helpful comparison separates the region the laboratory attempts to sequence, the changes its analysis is designed to detect, and the findings it agrees to report. These layers overlap, but they are not identical.
Imagine a hypothetical service that generates broad genome data but offers a report restricted to a particular group of genes. Its data collection is broad, while its current interpretation is focused. Another service might examine fewer regions but provide a detailed clinical analysis for a specific question. Reading only the word “genome” would not reveal that distinction.
Ask for a plain-language description of all three layers. Request the gene list or reporting scope when relevant, along with the limitations section. Our comparison of genotyping and sequencing explains another distinction that can otherwise become confused with the genome-versus-exome choice.
Why “whole” does not mean perfect detection
Genetic changes take different forms. They may involve a single DNA base, a small insertion or deletion, a larger missing or duplicated segment, or an expanded repeated sequence. Different laboratory methods and analysis procedures have different capabilities for finding them.
Exome sequencing can leave relevant noncoding changes outside its main target. Both exome and genome approaches can have technical limitations, and some questions require additional methods. Research from the Undiagnosed Diseases Network has documented diagnoses that required testing beyond exome sequencing, including evaluation of noncoding variants, copy-number changes, repeat expansions, or methylation. That finding illustrates why the test's limitations matter; it is not a prediction of anyone's chance of receiving a diagnosis.
Ask which classes of variants the particular test is validated to detect. If a brochure names a condition, ask whether the method covers the kinds of changes associated with it. A broad label is not a substitute for that answer.
What does coverage mean?
Sequencing coverage describes how the generated reads represent a region of DNA. Depth refers to how many reads cover a position; breadth concerns how much of the intended region is represented at a stated level. An average figure can hide differences between regions.
You do not need to choose a numerical threshold yourself to ask a useful question. Ask the laboratory or ordering professional how it handles poorly covered regions that matter to the clinical question. Are they identified in the report? Can another method fill a gap? Are some regions excluded from interpretation?
This turns a technical measurement into a practical discussion about unanswered questions. It also avoids assuming that two services using the same sequencing label have identical performance.
The reason for testing still guides the choice
Clinical genetic testing may focus on one known familial variant, a single gene, a panel of genes, or a broader analysis. The appropriate scope depends partly on the question and the types of genetic changes being investigated. A larger test is not automatically the clearest answer to a narrowly defined question.
For example, “Was this specific family variant inherited?” differs from “Could a genetic explanation account for an unexplained combination of findings?” These hypothetical questions require different discussions about scope. Neither one can be resolved simply by choosing the largest number in a product comparison.
Ask what additional information genome sequencing could provide over exome sequencing in the particular evaluation. Also ask what a focused test could answer, and what would remain unknown after each option.
Finding a variant and explaining it are different steps
Sequencing produces observations about DNA. Interpretation evaluates whether a finding is relevant to the question, taking account of the available evidence and clinical context. A variant can be detected clearly while its health significance remains uncertain.
A variant of uncertain significance does not establish a diagnosis. A result that does not identify an explanation also does not prove that the question has no genetic component. Our guide to reading genetic test results explains why positive, negative, and uncertain results need to be read within the scope of the test.
Before testing, ask how the report distinguishes a relevant finding from an unresolved possibility. Also ask who will discuss that distinction with you, especially if the report is delivered electronically before a scheduled appointment.
Decide how to handle findings beyond the original question
Broad sequencing can identify variants connected to a condition other than the reason the test was ordered. Laboratories may have a defined policy for actively evaluating and reporting certain secondary findings. The presence of broad sequence data does not mean that every possible health association will be assessed.
Ask what categories are included, what choices are available, and when those choices must be made. Discuss how unexpected findings would be explained and whether another test might be needed to clarify them. Questions about secondary findings belong in the consent conversation before the sample is analyzed. Ask whether declining a category changes the underlying analysis or simply what is returned to you; the distinction should be stated in the service’s consent materials.
If relatives' samples are proposed, ask why each sample is useful, what each participant is consenting to, and which results may be returned to them. A family testing plan should be understandable to each person involved.
Compare logistics and future access
Ask for the expected schedule for the complete process, including analysis and explanation, rather than just laboratory sequencing time. Request an estimate that identifies consultation, specimen collection, analysis, and any additional testing separately. A general statement about the cost of sequencing may leave out substantial parts of a clinical service.
Then ask about future review. Will the data be retained? Is reanalysis available if knowledge or the clinical question changes? Who initiates it, and is there a separate fee? Avoid treating possible future reinterpretation as a guaranteed update service.
Keep the original report and its date. If a later report changes the interpretation, comparing the versions can help explain whether the change arose from new evidence, a different analysis, or additional testing.
A focused set of questions for the conversation
- What specific question is this test intended to answer?
- Which regions, variant types, and reporting categories are included?
- What limitations remain even if no relevant finding is reported?
- How will uncertain or secondary findings be explained?
- What role could family information, further testing, or reanalysis play?
The useful choice connects technical scope to an answerable question and a clear interpretation process. Our genetic counseling preparation guide can help you bring those questions to a discussion. Genome and exome sequencing are powerful investigative tools; their value depends on understanding both the information they can provide and the uncertainty that may remain.
